Shealy Stephanie, Kohn Joseph, Yongue Emily, Troficanto Casey, Bookstaver P Brandon, Justo Julie Ann, Winders Hana R, Dash Sangita, Al-Hasan Majdi N
Department of Clinical Pharmacy and Outcomes Sciences, University of South Carolina College of Pharmacy, Columbia, SC 29208, USA.
Department of Clinical Pharmacy, Prisma Health-Midlands, Columbia, SC 29203, USA.
Pharmacy (Basel). 2021 Feb 7;9(1):32. doi: 10.3390/pharmacy9010032.
The standardized antimicrobial administration ratio (SAAR) is a novel antimicrobial stewardship metric that compares actual to expected antimicrobial use (AU). This prospective cohort study examines the utility of SAAR reporting and inter-facility comparisons as a motivational tool to improve overall and broad-spectrum AU within a three-hospital healthcare system. Transparent inter-facility comparisons were deployed during system-wide antimicrobial stewardship meetings beginning in October 2017. Stakeholders were advised to interpret the results to foster competition and incorporate SAAR data into focused antimicrobial stewardship interventions. Student's -test was used to compare mean SAARs in the pre- (July 2017 through October 2017) and post-intervention periods (November 2017 through June 2019). The mean pre-intervention SAARs for hospitals A, B, and C were 0.69, 1.09, and 0.60, respectively. Hospital B experienced significant reductions in SAAR for overall AU (from 1.09 to 0.83; < 0.001), broad-spectrum antimicrobials used for hospital-onset infections (from 1.36 to 0.81; < 0.001), and agents used for resistant gram-positive infections in the intensive care units (from 1.27 to 0.72; < 0.001) after the interventions. The alignment of the SAAR across the health-system and sustained reduction in overall and broad-spectrum AU through implementation of inter-facility comparisons demonstrate the utility in the motivational application of this antimicrobial use metric.
标准化抗菌药物使用比例(SAAR)是一种新型的抗菌药物管理指标,用于比较实际抗菌药物使用量(AU)与预期使用量。这项前瞻性队列研究考察了SAAR报告和机构间比较作为一种激励工具,在一个由三家医院组成的医疗系统中改善整体和广谱抗菌药物使用情况的效用。从2017年10月开始,在全系统抗菌药物管理会议期间进行了透明的机构间比较。建议利益相关者解读结果以促进竞争,并将SAAR数据纳入有针对性的抗菌药物管理干预措施中。采用学生t检验比较干预前(2017年7月至2017年10月)和干预后时期(2017年11月至2019年6月)的平均SAAR。医院A、B和C干预前的平均SAAR分别为0.69、1.09和0.60。干预后,医院B的整体抗菌药物使用SAAR显著降低(从1.09降至0.83;P<0.001),用于医院获得性感染的广谱抗菌药物(从1.36降至0.81;P<0.001),以及重症监护病房用于耐革兰氏阳性菌感染的药物(从1.27降至0.72;P<0.001)。通过实施机构间比较,全卫生系统SAAR的一致性以及整体和广谱抗菌药物使用量的持续下降证明了该抗菌药物使用指标在激励应用方面的效用。